REG - Seneca Growth Cap. Seneca Growth-SVCT - Net Asset Value(s)

Seneca Growth Capital VCTAnnouncement

03/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250403:nRSC4213Da&default-theme=true

RNS Number : 4213D  Seneca Growth Capital VCT PLC  03 April 2025

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

3 April 2025

Net asset values ("NAV")

The Directors and the Investment Manager of the Company, Seneca Partners
Limited ("Seneca"), have reviewed the valuation of the Company's Ordinary and
B share investment portfolios and announce an updated NAV for each of the
share classes as at 31 March 2025.

B Shares

As at 31 March 2025, the unaudited NAV per B share was 49.8p and it is
intended that this is the NAV per B share which will be used for the planned
allotment of B shares on 4 April 2025.

This is a decrease of 2.0p from the unaudited NAV per B share as at 31
December 2024, which was 51.8p, full details of which will be included in our
Final Results announcement later this month.

The 31 March 2025 unaudited NAV also represents a decrease of 3.5p compared to
the latest published unaudited NAV of 53.3p as at 30 September 2024.

The decrease in B share NAV continues to be as a result of a reduction in the
share prices of the B share pool's AIM quoted investments.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as
at 31 March 2025 was 67.8p.

The B share Offer by the Company remains open for the 2024/25 tax year until
midday today, 3 April 2025.

The B share Offer remains open for the 2025/26 tax year until 8 August 2025,
unless the Offer has been fully subscribed by an earlier date or is closed
earlier at the discretion of the Directors.

Ordinary Shares

As at 31 March 2025, the unaudited NAV per Ordinary share was 12.9p.

This is a decrease of 3.8p from the unaudited NAV per Ordinary share as at 31
December 2024, which was 16.7p, full details of which will be included in our
Final Results announcement later this month.

The 31 March 2025 unaudited NAV also represents a decrease of 7.5p compared to
the latest published unaudited NAV of 20.4p as at 30 September 2024.

The decrease in Ordinary share NAV is principally due to a reduction in the
value of the Ordinary share pool's AIM quoted investments in Scancell Holdings
Plc and Arecor Therapeutics Plc. The closing bid price of Scancell Holdings
Plc shares on 31 March 2025 was 7.8p per share (30 September 2024: 14p) and
the closing bid price of Arecor Therapeutics Plc shares on 31 March 2025 was
42.0p per share (30 September 2024: 62p).

The unaudited NAV total return per Ordinary share (NAV plus cumulative
dividends) as at 31 March 2025 was 86.2p.

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation No 596/2014 which is part of English
law by virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

For further information, please contact:

Richard Manley, Seneca Growth Capital VCT Plc
at Richard.Manley@senecapartners.co.uk
(https://www.globenewswire.com/Tracker?data=kcQq_uG46lOY1OR3s35M-cO_-Mev2AlmUGZyg51sRAJAnHqPB51wpVD1s-rE61kaF5m6AOC2jUOs-R7Bcth1u_AvCgI62k3LL-aUbjADJvlPT16Fahfo25SPdrPOuVym0X5u6WJmlQ2wTEQmd4pEBQsrgqtzJb_3aTgfX9c_ZR7nFRDN2qC9omho-NytytbhRg92m_pCTYkWJ-FbNd2jpBYc4pC9FETVDEI3bApr1I3QmEId1oUYrHcWBQTyN1xSRLDY8VS9q7kcAVkP6vr9umW1QT2-D4AeAI0bLPrfo36Go7t5vJTTBXl26eeXdUsQt26zl977AxcSuf48DAkWFg==)

Any enquiries regarding the offer for subscription of B shares should be
directed to:

Siobhan Pycroft at Seneca Partners Limited on 01942 295 981 or at
Siobhan.Pycroft@senecapartners.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NAVBLGDSXDGDGUD